Bladder Cancer Pharmacogenomics: Recent Insights and Future Perspectives

Abstract

PharmacogenomicsVol. 13, No. 14 EditorialBladder cancer pharmacogenomics: recent insights and future perspectivesPeter H O’DonnellPeter H O’DonnellDepartment of Medicine & Section of Hematology/Oncology, Committee on Clinical Pharmacology & Pharmacogenomics, & Center for Personalized Therapeutics, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. Search for more papers by this authorEmail the corresponding author at podonnel@medicine.bsd.uchicago.eduPublished Online:13 Nov 2012https://doi.org/10.2217/pgs.12.145AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: biomarkersbladder cancerpharmacogeneticspharmacogenomicsurothelial cancerReferences1 American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, GA, USA, 4, 10, 21 (2010).Google Scholar2 Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349,859–866 (2003).Crossref, Medline, CAS, Google Scholar3 von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol.18,3068–3077 (2000).Crossref, Medline, CAS, Google Scholar4 Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol.29,3443–3449 (2011).Crossref, Medline, CAS, Google Scholar5 Rosenberg CL. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J. Clin. Oncol.26,4856–4858 (2008).Crossref, Medline, Google Scholar6 Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev.33,565–577 (2007).Crossref, Medline, CAS, Google Scholar7 Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol.18,522–528 (2007).Crossref, Medline, CAS, Google Scholar8 Sun JM, Sung JY, Park SH et al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer12,187 (2012).Crossref, Medline, CAS, Google Scholar9 Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res.11,2625–2636 (2005).Crossref, Medline, CAS, Google Scholar10 Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci.98,113–117 (2007).Crossref, Medline, CAS, Google Scholar11 Takata R, Obara W, Fujioka T. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer. Aktuelle Urol.41(Suppl. 1),S41–S45 (2010).Crossref, Medline, Google Scholar12 Lee JK, Havaleshko DM, Cho H et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA104,13086–13091 (2007).Crossref, Medline, CAS, Google Scholar13 Havaleshko DM, Cho H, Conaway M et al. Prediction of drug combination chemosensitivity in human bladder cancer. Mol. Cancer Ther.6,578–586 (2007).Crossref, Medline, CAS, Google Scholar14 Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res.69,8302–8309 (2009).Crossref, Medline, CAS, Google Scholar15 Griffiths G, Hall R, Sylvester R et al. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol.29,2171–2177 (2011).Crossref, Medline, CAS, Google Scholar16 Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48,202–205 (2005).Crossref, Medline, Google Scholar17 David KA, Milowsky MI, Ritchey J et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol.178,451–454 (2007).Crossref, Medline, Google Scholar18 Raj GV, Karavadia S, Schlomer B et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer117,276–282 (2011).Crossref, Medline, CAS, Google Scholar19 O’Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol. Oncol.6,251–259 (2012).Crossref, Medline, Google Scholar101 National Cancer Institute. Organ Specific Workshops. http://trp.cancer.gov/information_for_public/organ_specific.htmGoogle Scholar102 Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer. http://www.clinicaltrials.gov/ct2/show/NCT01206426Google ScholarFiguresReferencesRelatedDetailsCited ByClinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial CancerClinical Genitourinary Cancer, Vol. 14, No. 6Diagnostic Microdosing Approach to Study Gemcitabine Resistance10 October 2016 | Chemical Research in Toxicology, Vol. 29, No. 11Pharmacogenomics in bladder cancerUrologic Oncology: Seminars and Original Investigations, Vol. 32, No. 1 Vol. 13, No. 14 Follow us on social media for the latest updates Metrics Downloaded 195 times History Published online 13 November 2012 Published in print November 2012 Information© Future Medicine LtdKeywordsbiomarkersbladder cancerpharmacogeneticspharmacogenomicsurothelial cancerFinancial & competing interests disclosureThe author has received funding from the NIH K12 CA139160 and The Cancer Research Foundation. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download